Detalles de la búsqueda
1.
Evaluation of T-cell clonality by anti-TRBC1 antibody-based flow cytometry and correlation with T-cell receptor sequencing.
Br J Haematol;
204(3): 910-920, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38098188
2.
Computational flow cytometry provides accurate assessment of measurable residual disease in chronic lymphocytic leukaemia.
Br J Haematol;
202(4): 760-770, 2023 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37052611
3.
3D-ordered porous CdS/AgI/ZnO nanostructures for high-performance photoelectrochemical water splitting.
Nanotechnology;
34(46)2023 Aug 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-37551562
4.
OUTCOMES OF SWITCHING FROM PROACTIVE TO REACTIVE TREATMENT AFTER DEVELOPING ADVANCED CENTRAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Retina;
43(7): 1070-1080, 2023 07 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36893432
5.
Five-year corneal cross-linking outcomes: A Save Sight Keratoconus Registry Study.
Clin Exp Ophthalmol;
51(1): 9-18, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36240047
6.
Twenty-four-month real-life treatment outcomes of polypoidal choroidal vasculopathy versus type 1 macular neovascularization in Caucasians.
Clin Exp Ophthalmol;
51(8): 799-807, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37871984
7.
THE IMPACT OF DISEASE ACTIVITY ON 5-YEAR OUTCOMES IN PATIENTS UNDERGOING TREATMENT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Retina;
42(1): 95-106, 2022 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34292225
8.
INTERNATIONAL IMPACT OF THE COVID-19 PANDEMIC LOCKDOWN ON INTRAVITREAL THERAPY OUTCOMES: Fight Retinal Blindness Registry.
Retina;
42(4): 616-627, 2022 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34907129
9.
THREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA: Data from the Fight Retinal Blindness! Registry.
Retina;
42(6): 1085-1094, 2022 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35174799
10.
Tilapia Lake Virus was not detected in non-tilapine species within tilapia polyculture systems of Bangladesh.
J Fish Dis;
45(1): 77-87, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34580880
11.
Comparative study of 2-year outcomes for Hydrus or iStent inject microinvasive glaucoma surgery implants with cataract surgery.
Clin Exp Ophthalmol;
50(3): 303-311, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35077009
12.
Quality of life impact of eye diseases: a Save Sight Registries study.
Clin Exp Ophthalmol;
50(4): 386-397, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35080803
13.
One-year real-world outcomes of bevacizumab for the treatment of macular oedema secondary to retinal vein occlusion.
Clin Exp Ophthalmol;
50(9): 1038-1046, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-35869925
14.
Creation of a neovascular age-related macular degeneration national database using a web-based platform: Fight Retinal Blindness Spain. Report 1: Visual outcomes.
Clin Exp Ophthalmol;
50(3): 312-324, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35106882
15.
Treat-and-extend versus fixed bimonthly treatment regimens for treatment-naive neovascular age-related macular degeneration: real world data from the Fight Retinal Blindness registry.
Graefes Arch Clin Exp Ophthalmol;
259(6): 1463-1470, 2021 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-33219442
16.
FIVE-YEAR INCIDENCE AND VISUAL ACUITY OUTCOMES FOR INTRAVITREAL THERAPY IN BILATERAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Fight Retinal Blindness! Project.
Retina;
41(1): 118-124, 2021 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32310628
17.
ASSOCIATION BETWEEN ANATOMICAL AND CLINICAL OUTCOMES OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR.
Retina;
41(7): 1446-1454, 2021 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33332811
18.
Neovascular age-related macular degeneration: A review of findings from the real-world Fight Retinal Blindness! registry.
Clin Exp Ophthalmol;
49(7): 652-663, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34013534
19.
Neovascular age-related macular degeneration at treatment intervals of 14 weeks or greater.
Clin Exp Ophthalmol;
49(6): 570-578, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34129283
20.
Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.
Ophthalmology;
127(3): 369-376, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31757494